ML-9

ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity[3]. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively[1]. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation[3].

Product Specifications

CAS Number

[105637-50-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Myosin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ml-9.html

Purity

99.86

Solubility

DMSO : 83.33 mg/mL (ultrasonic) |H2O : ≥ 5 mg/mL

Smiles

O=S(N1CCNCCC1)(C2=C3C=CC=C(Cl)C3=CC=C2)=O.[H]Cl

Molecular Formula

C15H18Cl2N2O2S

Molecular Weight

361.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Ito S, et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis.Eur J Pharmacol. 2004 Feb 23;486 (3) :325-33.|[2]Shaikh S, et al. The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content.Toxicol In Vitro. 2018 Apr;48:121-127.|[3]Kondratskyi A1, et al.Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death.Cell Death Dis. 2014 Apr 24;5:e1193.